These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 25788702)

  • 1. Autophagy is required for stem cell mobilization by G-CSF.
    Leveque-El Mouttie L; Vu T; Lineburg KE; Kuns RD; Bagger FO; Teal BE; Lor M; Boyle GM; Bruedigam C; Mintern JD; Hill GR; MacDonald KP; Lane SW
    Blood; 2015 May; 125(19):2933-6. PubMed ID: 25788702
    [TBL] [Abstract][Full Text] [Related]  

  • 2. HIF-1α is required for hematopoietic stem cell mobilization and 4-prolyl hydroxylase inhibitors enhance mobilization by stabilizing HIF-1α.
    Forristal CE; Nowlan B; Jacobsen RN; Barbier V; Walkinshaw G; Walkley CR; Winkler IG; Levesque JP
    Leukemia; 2015 Jun; 29(6):1366-78. PubMed ID: 25578474
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Sphingosine-1-phosphate facilitates trafficking of hematopoietic stem cells and their mobilization by CXCR4 antagonists in mice.
    Juarez JG; Harun N; Thien M; Welschinger R; Baraz R; Pena AD; Pitson SM; Rettig M; DiPersio JF; Bradstock KF; Bendall LJ
    Blood; 2012 Jan; 119(3):707-16. PubMed ID: 22049516
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hematopoietic stem cell mobilizing agents G-CSF, cyclophosphamide or AMD3100 have distinct mechanisms of action on bone marrow HSC niches and bone formation.
    Winkler IG; Pettit AR; Raggatt LJ; Jacobsen RN; Forristal CE; Barbier V; Nowlan B; Cisterne A; Bendall LJ; Sims NA; Lévesque JP
    Leukemia; 2012 Jul; 26(7):1594-601. PubMed ID: 22266913
    [TBL] [Abstract][Full Text] [Related]  

  • 5. AMD3100 mobilizes hematopoietic stem cells with long-term repopulating capacity in nonhuman primates.
    Larochelle A; Krouse A; Metzger M; Orlic D; Donahue RE; Fricker S; Bridger G; Dunbar CE; Hematti P
    Blood; 2006 May; 107(9):3772-8. PubMed ID: 16439684
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Plerixafor plus granulocyte colony-stimulating factor versus placebo plus granulocyte colony-stimulating factor for mobilization of CD34(+) hematopoietic stem cells in patients with multiple myeloma and low peripheral blood CD34(+) cell count: results of a subset analysis of a randomized trial.
    Nademanee AP; DiPersio JF; Maziarz RT; Stadtmauer EA; Micallef IN; Stiff PJ; Hsu FJ; Bridger G; Bolwell BJ
    Biol Blood Marrow Transplant; 2012 Oct; 18(10):1564-72. PubMed ID: 22683613
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Rapid mobilization of murine and human hematopoietic stem and progenitor cells with AMD3100, a CXCR4 antagonist.
    Broxmeyer HE; Orschell CM; Clapp DW; Hangoc G; Cooper S; Plett PA; Liles WC; Li X; Graham-Evans B; Campbell TB; Calandra G; Bridger G; Dale DC; Srour EF
    J Exp Med; 2005 Apr; 201(8):1307-18. PubMed ID: 15837815
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effective mobilization of hematopoietic progenitor cells in G-CSF mobilization defective CD26-/- mice through AMD3100-induced disruption of the CXCL12-CXCR4 axis.
    Paganessi LA; Walker AL; Tan LL; Holmes I; Rich E; Fung HC; Christopherson KW
    Exp Hematol; 2011 Mar; 39(3):384-90. PubMed ID: 21168468
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Diabetes Limits Stem Cell Mobilization Following G-CSF but Not Plerixafor.
    Fadini GP; Fiala M; Cappellari R; Danna M; Park S; Poncina N; Menegazzo L; Albiero M; DiPersio J; Stockerl-Goldstein K; Avogaro A
    Diabetes; 2015 Aug; 64(8):2969-77. PubMed ID: 25804941
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Plerixafor: A chemokine receptor-4 antagonist for mobilization of hematopoietic stem cells for transplantation after high-dose chemotherapy for non-Hodgkin's lymphoma or multiple myeloma.
    Steinberg M; Silva M
    Clin Ther; 2010 May; 32(5):821-43. PubMed ID: 20685493
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Plerixafor (AMD3100) and granulocyte colony-stimulating factor (G-CSF) mobilize different CD34+ cell populations based on global gene and microRNA expression signatures.
    Donahue RE; Jin P; Bonifacino AC; Metzger ME; Ren J; Wang E; Stroncek DF
    Blood; 2009 Sep; 114(12):2530-41. PubMed ID: 19602709
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Plerixafor, a CXCR4 antagonist for the mobilization of hematopoietic stem cells.
    Uy GL; Rettig MP; Cashen AF
    Expert Opin Biol Ther; 2008 Nov; 8(11):1797-804. PubMed ID: 18847313
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [The effect of matrix metalloproteinase-9 in granulocyte colony stimulation factor-induced stem cell mobilization].
    Jin FY; Qiu LG; Li QC; Meng HX; Wang YF; Yu Z; Li Q; Han JL
    Zhonghua Yi Xue Za Zhi; 2006 Nov; 86(42):2966-70. PubMed ID: 17288807
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Plerixafor and granulocyte-colony-stimulating factor (G-CSF) in patients with lymphoma and multiple myeloma previously failing mobilization with G-CSF with or without chemotherapy for autologous hematopoietic stem cell mobilization: the Austrian experience on a named patient program.
    Worel N; Rosskopf K; Neumeister P; Kasparu H; Nachbaur D; Russ G; Namberger K; Witt V; Schloegl E; Zojer N; Linkesch W; Kalhs P; Greinix HT
    Transfusion; 2011 May; 51(5):968-75. PubMed ID: 20880037
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Recent advances on the use of the CXCR4 antagonist plerixafor (AMD3100, Mozobil™) and potential of other CXCR4 antagonists as stem cell mobilizers.
    De Clercq E
    Pharmacol Ther; 2010 Dec; 128(3):509-18. PubMed ID: 20826182
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Unraveling stem cell and progenitor subsets in autologous grafts according to methods of mobilization: implications for prediction of hematopoietic recovery.
    Roug AS; Hokland LB; Segel E; Nielsen K; Toft-Petersen M; Van Kooten Niekerk PB; Hokland P; Nederby L
    Cytotherapy; 2014 Mar; 16(3):392-401. PubMed ID: 24424268
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mobilization of hematopoietic stem cells with highest self-renewal by G-CSF precedes clonogenic cell mobilization peak.
    Winkler IG; Wiercinska E; Barbier V; Nowlan B; Bonig H; Levesque JP
    Exp Hematol; 2016 Apr; 44(4):303-14.e1. PubMed ID: 26827874
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Plerixafor plus granulocyte colony-stimulating factor improves the mobilization of hematopoietic stem cells in patients with non-Hodgkin lymphoma and low circulating peripheral blood CD34+ cells.
    Maziarz RT; Nademanee AP; Micallef IN; Stiff PJ; Calandra G; Angell J; Dipersio JF; Bolwell BJ
    Biol Blood Marrow Transplant; 2013 Apr; 19(4):670-5. PubMed ID: 23333777
    [TBL] [Abstract][Full Text] [Related]  

  • 19. In vivo activity of the cleaved form of soluble urokinase receptor: a new hematopoietic stem/progenitor cell mobilizer.
    Selleri C; Montuori N; Ricci P; Visconte V; Baiano A; Carriero MV; Rotoli B; Rossi G; Ragno P
    Cancer Res; 2006 Nov; 66(22):10885-90. PubMed ID: 17108125
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Plerixafor on demand in ten healthy family donors as a rescue strategy to achieve an adequate graft for stem cell transplantation.
    Gattillo S; Marktel S; Rizzo L; Malato S; Malabarba L; Coppola M; Assanelli A; Milani R; De Freitas T; Corti C; Bellio L; Ciceri F
    Transfusion; 2015 Aug; 55(8):1993-2000. PubMed ID: 25721167
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.